Refractory B-cell Acute Lymphoblastic Leukemia Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about Refractory B-cell Acute Lymphoblastic Leukemia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 15 of 5 trials

Recruiting
Phase 1

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

Relapsed or Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed or Refractory B-cell Non-Hodgkin Lymphoma
Autolus Limited30 enrolled8 locationsNCT06173518
Recruiting
Phase 1

A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.33 enrolled8 locationsNCT06927466
Recruiting
Phase 2

CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL

Relapsed B-cell Acute Lymphoblastic LeukemiaRefractory B-cell Acute Lymphoblastic Leukemia
Beijing Yongtai Ruike Biotechnology Company Ltd100 enrolled1 locationNCT06179524
Recruiting
Phase 1

CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma, RelapsedNon-Hodgkin's Lymphoma RefractoryRelapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Institute of Hematology and Blood Transfusion, Czech Republic10 enrolled1 locationNCT05054257
Recruiting
Phase 1Phase 2

Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL

Relapse/Refractory B-cell Acute Lymphoblastic Leukemia
Kara Yakhteh Tajhiz Azma Company5 enrolled1 locationNCT06635330